Comparison 1. Progestagen versus no adjuvant treatment.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Overall survival	1		Hazard Ratio (Random, 95% CI)	Subtotals only
2 Death from any cause	7		Risk Ratio (IV, Random, 95% CI)	Subtotals only
2.1 At 4 years	1	570	Risk Ratio (IV, Random, 95% CI)	1.63 [1.00, 2.67]
2.2 At 5 years	5	2682	Risk Ratio (IV, Random, 95% CI)	0.86 [0.56, 1.32]
2.3 At 5 years (excluding Urbanski)	4	2477	Risk Ratio (IV, Random, 95% CI)	1.00 [0.85, 1.18]
2.4 At 7 years	1	718	Risk Ratio (IV, Random, 95% CI)	1.15 [0.75, 1.77]
3 Death from endometrial cancer	2		Risk Ratio (IV, Random, 95% CI)	Subtotals only
3.1 At 5 years	1	35	Risk Ratio (IV, Random, 95% CI)	1.89 [0.19, 18.97]
3.2 At 7 years	1	718	Risk Ratio (IV, Random, 95% CI)	1.48 [0.82, 2.66]
4 Non‐cancer related deaths at 7 years	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
5 Death due to cardiovascular disease	2		Risk Ratio (IV, Random, 95% CI)	Subtotals only
5.1 At 2 years	1	1084	Risk Ratio (IV, Random, 95% CI)	3.52 [0.99, 12.55]
5.2 At 4 years	1	1084	Risk Ratio (IV, Random, 95% CI)	1.03 [0.49, 2.18]
5.3 At 7 years	1	718	Risk Ratio (IV, Random, 95% CI)	0.83 [0.31, 2.20]
6 Recurrence‐free survival	1		Hazard Ratio (Random, 95% CI)	Subtotals only
7 Disease recurrence	2		Risk Ratio (IV, Random, 95% CI)	Totals not selected
7.1 At 5 years	1		Risk Ratio (IV, Random, 95% CI)	0.0 [0.0, 0.0]
7.2 At 7 years	1		Risk Ratio (IV, Random, 95% CI)	0.0 [0.0, 0.0]
8 Adverse Events: Hypertension	1		Risk Ratio (IV, Random, 95% CI)	Subtotals only